Inclisiran: A Game Changer in a Changing Game?

J Am Coll Cardiol. 2021 Mar 9;77(9):1194-1196. doi: 10.1016/j.jacc.2021.01.008.

Authors

Vijay Nambi¹, Ali Agha²

Affiliations

¹ Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA; Department of Medicine and Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, Houston, Texas, USA. Electronic address: vnambi@bcm.edu.
² Department of Medicine and Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, Houston, Texas, USA. Electronic address: https://twitter.com/AliAghaBCM.

PMID: 33663736
DOI: 10.1016/j.jacc.2021.01.008

No abstract available

Keywords: ASCVD; PCSK9-inhibitor; inclisiran; lipid-lowering therapy; low-density lipoprotein-cholesterol; safety.

Publication types

Editorial
Comment

MeSH terms

Humans
Proprotein Convertase 9*
RNA, Small Interfering

Substances

ALN-PCS
RNA, Small Interfering
Proprotein Convertase 9